NY-VIACOMCBS
20.10.2020 14:47:11 CEST | Business Wire | Press release
ViacomCBS Networks International (VCNI), a division of ViacomCBS Inc. (NASDAQ: VIAC), has today confirmed the departure of one of its longest serving executives, Pierluigi Gazzolo, who will step down from his role as President, Streaming and Studios for VCNI at the end of this month to focus on other interests.
During Gazzolo’s tenure as President of Streaming and Studios for VCNI, he successfully established the content proposition, team and go to market strategy for the international launch of Paramount+ and expanded the roadmap for Pluto TV internationally.
VCNI Streaming Leadership
Reporting to David Lynn, President and CEO of VCNI, and working closely with Tom Ryan, President & CEO of ViacomCBS Streaming, Kelly Day, Chief Operating Officer of VCNI, will take over leadership of the division’s streaming business as President of Streaming and COO of VCNI. In this new role, Day will have oversight of the international roll-out of Paramount+, a new premium SVOD service due to launch in 2021 across Australia, Latin America, and the Nordics; as well as the ongoing expansion of Pluto TV, following its successful launch in Latin America.
Regarding Day’s expanded remit, Lynn added, “We are in the fortunate position of going from strength to strength with this transition. With a truly global streaming organization, it’s a pivotal moment in the evolution of our streaming strategy, with the expansion of Paramount+ and Pluto TV, both of which are critical to our future growth. Kelly has an enviable track record of launching and growing streaming businesses and has added a layer of extraordinary digital expertise to our management team in a short space of time. Now, also, working closely with Tom Ryan, I’m confident Kelly will accelerate our transition to becoming a more digitally-led business, while seizing our global streaming opportunity.”
ViacomCBS International Studios Leadership
ViacomCBS Studios International (VIS) will supply original content to the new Paramount+ service in some markets, while continuing to supply scripted, comedy and reality series to VCNI’s free and pay TV networks as well as third party streamers and broadcasters.
Also, reporting to Lynn, JC Acosta, who oversees VCNI’s operations in Latin America and Canada as President, VCN Americas, will take on additional responsibility as President, ViacomCBS International Studios.
Lynn added, “One of our biggest achievements in recent years has been the formation and expansion of VIS, which really couldn’t have happened without Pier’s vision. In the past year, under Pier’s leadership he doubled the global development slate, setting VCNI up for continued global success in the studios arena.”
“Now with JC’s expertise in production and development, coupled with his drive and dedication its incredibly reassuring that JC will take over leadership of VIS,” said Lynn. “Given JC’s intimate understanding of our Studios business, his connections and his knowledge of the international content market, we couldn’t be better positioned for continued growth.”
Gazzolo’s Tenure
Paying tribute to Gazzolo, Lynn said, “While he will hate to be labelled as a veteran, there’s no better word to describe someone who has dedicated so much of his career to our company and who has benefited it so much with his wisdom and experience. He’s a brilliant all-rounder who has played in many positions for our team, but always with the same outstanding results. It’s typical of Pier’s commitment that he’s stayed to oversee a seamless handover to Kelly and JC, even though he’s been signaling his interest in pursuing his own projects for some time. I can’t thank him enough for his contribution to our business over many years. I know everyone at VCNI will join me in genuinely wishing him well in his future endeavors.”
Gazzolo commented, “I’ve grown up with this amazing company. From MTV Latino, to MTV Networks to Viacom International Media Networks to post merger ViacomCBS Networks International. I’ve been honored to grow and evolve with ViacomCBS, and I’m immensely grateful to have worked across so many regions and divisions at the most dynamic media company in the world. I have benefited tremendously from having worked with unparalleled leaders and mentors, throughout my tenure, but especially in the latest chapter of my term. Most importantly I’ve created wonderful close friendships in my 27 years with the company – and those will continue long after I leave the building.”
About Pierluigi Gazzolo
Prior to taking up his current role as President, Streaming and Studios in November 2019, Pierluigi Gazzolo was President, Americas for Viacom International Media Networks, which was renamed as VCNI after the ViacomCBS merger in December last year.
Based in Miami, he oversaw a marked expansion of the company’s operations across Spanish-speaking Latin America and Brazil, spearheaded by two key acquisitions – ownership of Argentina’s leading free-to-air broadcaster, Telefe (2016), and a majority stake in Brazilian comedy producer, Porta dos Fundos (2017). Combining Telefe’s studios business and Porta dos Fundos with VIMN’s existing production activities in the region, Gazzolo formed VIS and secured its first sales to both Netflix and Amazon Prime, as well as a host of other deals with broadcasters and streamers across the region. Under his leadership, VIS has expanded its production activities in the UK, Europe, and Asia.
At the same time as leading the company’s operations in Latin America, Gazzolo continued to lead Nickelodeon internationally, giving him oversight of this critical brand in all markets outside the U.S. In this role, he oversaw an increase in international supply to Nickelodeon’s global content pipeline with locally developed shows being remade for global distribution, including Talia in the Kitchen and Every Witch Way.
Previously, Gazzolo was Chief Operating Officer for VIMN (2011 to 2014) and its predecessor MTV Networks International (2009 to 2011), reporting in both roles to Bob Bakish, who is now CEO, ViacomCBS Inc. Before 2009, he held several different roles with the company including serving as President of MTV Networks Latin America.
ViacomCBS Networks International:
ViacomCBS Networks International, a unit of ViacomCBS Inc. (NASDAQ: VIAC), comprises many of the world’s most iconic entertainment brands, including Network 10, Channel 5, Telefe, Viacom 18, ViacomCBS International Studios, Nickelodeon, MTV, Comedy Central, BET, Paramount Network and Pluto TV. In addition to offering innovative streaming services and digital video products, ViacomCBS Networks International provides powerful capabilities in production, distribution and advertising solutions for partners on five continents and across more than 180 countries.
VIAC-IR
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005683/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
